Product Description
Mechanisms of Action: UV Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | India | Ireland | Pakistan | United Arab Emirates | United States
Approved Indications: None
Known Adverse Events: None
Company: Food and Drug Administration (FDA)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SCR-005 | P1 |
Completed |
Healthy Volunteers |
2019-02-18 |
|
NCT05865431 | N/A |
Completed |
Skin Cancer |
2018-02-02 |